SERVATUS Biopharmaceuticals

SERVATUS LIMITED

Shareholder Update, H2 FY2026

Dear Shareholders,

I am pleased to provide an update on Servatus for H2 FY2026 following a year of strong commercial growth, increasing operational capability and important strategic progress.

FY2026 demonstrated the strength of the Biomiq platform, with significant growth in sales, improving customer retention and continued investment in the systems, manufacturing capability and marketing infrastructure required to support future scale. Importantly, this progress has given the Company both the confidence and capability to plan for the next phase of growth.

The experience, customer insight and commercial capabilities developed through Biomiq's successful ecommerce-led acne business now provide a strong foundation for expansion into substantially larger skin health and skin longevity markets. By extending our scientific expertise into these categories, we believe Servatus is well positioned to build on the momentum already established and pursue a much broader long-term growth opportunity.

Biomiq Sales Grow 205%

Biomiq generated FY2026 sales of $1. 9 million, compared with $615k in FY2025, representing growth of approximately 205%.

The half-year progression is also encouraging:

- H2 FY2026 sales were $1.05 million, compared with $434k in H2 FY2025, representing growth of approximately 141%.
- H2 FY2026 was also approximately 26% higher than H1 FY2026, demonstrating continued growth from an increasingly larger revenue base, especially noting H1 FY2026 includes the most high velocity period of the year for eCommerce Black Friday/Cyber Monday.

Quarterly sales increased from $317k in Q1 FY2026 to $516k in Q2 and $571k in Q3, before moderating to $475k in Q4 due to lower spend on customer acquisition. Average order value also strengthened, reaching $104 in Q4 FY2026 up from $86 in Q1 FY2026.



Over 50% of Sales from Returning Customers

Just as importantly, customer retention continues to improve. Returning customers represented 33.3% of sales in Q1 FY2026, 34.2% in Q2, 38.6% in Q3 and 51.2% in Q4. This is particularly encouraging given the Company's continued investment in new-customer acquisition which drives long term value by converting new customer into more profitable returning customers. Increasing repeat purchasing alongside strong customer growth provides important evidence that consumers are not simply trying Biomiq, they are returning to it.



We also saw a significant improvement in contribution margins in Q4 FY2026 at ~10% of sales.

From Acne Brand to Skin Health Company

While the existing business continues to perform strongly, its current concentration also demonstrates the scale of the opportunity ahead. To date, Biomiq sales have been generated almost exclusively from acne-related products sold through ecommerce channels. This market has validated our ability to execute in sales and marketing to now unlock the full potential of our microbiome skincare product capability.

We are now broadening our commercial reach. Our vision and positioning of Biomiq is that we are building a science-led skin health company with broad applications to multiple market demographics.

Our future positioning is centred on healthy skin biology, including three key benefits; supporting the skin barrier, modulating the skin microbiome, and supporting skin cell biology - through functional approaches to address inflammation and cellular senescence/skin ageing caused by the accumulation of cells that are no longer functioning.

This allows Biomiq to remain highly relevant to our existing acne customers, many of whom are mothers buying for their children, while extending the brand into substantially larger consumer markets, including anti-aging and skin longevity, which are highly relevant to our existing customer base and have true mass market appeal.

Skin Longevity: A New Consumer Market

The most significant near-term opportunity is the launch of our new Bio-Rejuvenation skincare platform, led by a serum combining peptide technology with Biomiq's proprietary BioQx technology.
The product is intended to establish Biomiq in the adult skincare market, with relevance to women experiencing changing skin needs associated with peri-menopause, menopause and ageing.

It introduces Biomiq to a substantially larger consumer market (in fact the largest subsection of the skincare and cosmetic global market), supports premium pricing and attractive margins, and provides the foundation for a broader portfolio addressing skin health and appearance throughout adult life.

Our guiding brand philosophy is - Biomiq: A new era of science backed skincare.

The new Biomiq website is located at www.biomiqskincare.com

The broader brand positioning has been developed to support this transition and present the Company as a sophisticated, science-led skin health business.

Capital Position and Growth Capacity

The Company successfully completed its rights issue earlier this year, raising approximately $3.3 million. With the exception of $800,000 requested by two shareholders for payment in October this year, the funds have been received and the associated shares issued.

I would like to sincerely thank all shareholders for their continued support. This strengthened capital position provides the Company with the capacity to accelerate growth, which remains the primary driver of shareholder value over the next 12–18 months.

As we accelerate investment in growth opportunities, maintaining disciplined cash-flow management remains a priority. Management continues to balance investment in the Company’s growth with maintaining sufficient capital to support the business through this next phase.

Strengthening Leadership and Governance

In April 2026, Peter Brannighan joined the Board as Chairman.

Peter brings extensive public and private company board and senior management experience across Australia and the United Kingdom. We have already benefitted from his experience and background in strategic planning, finance, capital raising, ecommerce, marketing and organisational change.

Peter currently serves as Chairman of Tahbilk Wine Group and RPM Group and has previously held Chairman and senior board positions across a wide range of listed and unlisted companies.

We also welcomed Zoë Phillips as Chief Marketing Officer. Zoë brings more than 20 years of international brand and marketing experience across Australia, Europe and the United States, including experience in beauty, wellness, technology and high-growth consumer brands.

Her impact on our brand positioning and marketing strategy has been both positive and immediate since joining us.

Both appointments materially strengthen the Company's leadership capability as we move into a more ambitious phase of growth.

Live Biotherapeutic Platform

Biomiq remains the Company's immediate commercial priority.

At the same time, Servatus continues to preserve the scientific, clinical and intellectual property value contained within its live biotherapeutic drug development platform.

We continue to pursue non-dilutive funding, strategic partnerships and international investment opportunities capable of progressing these assets without diverting capital required to support the growth of the consumer business.

Looking Forward

The position of the Company entering the next phase is considerably stronger than it was twelve months ago.

We have:

- grown annual sales from $616k to $1.9 million;
- materially increased repeat customer purchasing;
- improved underlying commercial economics;
- expanded manufacturing and operational capability;
- strengthened the Board and management team;
- developed products addressing substantially larger consumer markets;
- repositioned Biomiq around the broader concept of science-led skin health; and
- progressed our first significant international distribution opportunity.

The existing business provides an increasingly strong foundation. The opportunity ahead is to build substantially upon it.

Our priorities are straightforward: continue growing the existing business, successfully launch the Skin Longevity platform, broaden the demographics and markets to in Biomiq can market products, expand distribution domestically and internationally, and maintain disciplined management of capital as we scale.

There will, inevitably, be challenges, particularly in managing cash requirements through a period of rapid growth, of which the completion of the rights issue capital raise and the timely receipt of our R&D rebate this year will be instrumental. However, the combination of product performance, strengthening customer retention, new product opportunities and broader market positioning give us considerable confidence in the direction of the Company.

We remain ambitious about what Biomiq can become and focused on the disciplined execution required to achieve it.

Thank you for your continued support.

Kind regards,

Mark Williams
Chief Executive Officer
Servatus Limited